Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Number of items: 27.

Journal Article

Abdulla, D. S. Y., Nogova, L., Riedel, R., Scheftler, M., Fischer, R. N., Michels, S., Heydt, C., Ihle, M. A., Fassunke, J., Merkelbach-Bruse, S., Buettner, R. and Wolf, J. (2018). NTRK1/2/3 gene rearrangements define a new and clinically actionable molecular subset of oncogene-driven cancers. Oncol. Res. Treat., 41. S. 293 - 294. BASEL: KARGER. ISSN 2296-5262

Alidousty, C., Baar, T., Martelotto, L. G., Heydt, C., Wagener, S., Fassunke, J., Duerbaum, N., Scheel, A., Frank, S., Holz, B., Binot, E., Kron, A., Merkelbach-Bruse, S., Ihle, M., Wolf, J., Buettner, R. and Schultheis, A. M. (2018). Genetic instability and recurrent MYC amplification in ALK-translocated NSCLC; a central role of TP53 mutations. Virchows Arch., 473. S. S315 - 1. NEW YORK: SPRINGER. ISSN 1432-2307

Ball, M., Fassunke, J., Heydt, C., Fischer, J., Schallenberg, S., Joehrens, K. and Merkelbach-Bruse, S. (2020). External quality assessment of immunohistochemistry, in-situ hybridization and RNA/DNA sequencing for ROS1 testing reveals high concordance for all methods. Ann. Oncol., 31. S. S890 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041

Buettner, R. and Heydt, C. (2013). Biomarker analysis from a pathologist's view. Founding the rationale for personalised treatment of lung cancer. Bundesgesundheitsblatt-Gesund., 56 (11). S. 1502 - 1509. NEW YORK: SPRINGER. ISSN 1437-1588

Castiglione, R., Ihle, M. A., Heydt, C., Alidousty, C., Schultheis, A., Merkelbach-Bruse, S., Hermsen, M., Buettner, R. and Franchi, A. (2017). Molecular characterisation of sinunasal carcinomas. Virchows Arch., 471. S. S150 - 1. NEW YORK: SPRINGER. ISSN 1432-2307

Heydt, C., Baar, T., Wagener, S., Ihle, M. A., Carl, C., Fassunke, J., Buettner, R. and Merkelbach-Bruse, S. (2017). Comparison of custom designed gene panels for hybrid capture-based parallel sequencing in molecular pathology routine diagnostics. J. Mol. Diagn., 19 (2). S. S50 - 2. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1943-7811

Heydt, C., Kostenko, A., Merkelbach-Bruse, S., Wolf, J. and Buttner, R. (2016). ALK evaluation in the world of multiplex testing: Network Genomic Medicine (NGM): the Cologne model for implementing personalised oncology. Ann. Oncol., 27. S. 25 - 35. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

Heydt, C., Pappesch, R., Rehker, J., Wagener, S., Ihle, M. A., Siemanowski, J., Buettner, R., Fassunke, J. and Merkelbach-Bruse, S. (2018). Comparison of DNA- and RNA-based parallel sequencing approaches for the detection of MET Exon 14 skipping mutations. Virchows Arch., 473. S. S288 - 1. NEW YORK: SPRINGER. ISSN 1432-2307

Heydt, C., Pappesch, R., Stecker, K., Neumann, J., Buettner, R. and Merkelbach-Bruse, S. (2018). Evaluation of the TruSight Tumor 170 (TST170) assay and its value in clinical research. Ann. Oncol., 29. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

Klein, S., Heydt, C., Buettner, R., Hillmer, A. and Drebber, U. (2018). Malignant transformation of a hepatocellular adenoma in a male individual reveals insights into its molecular trajectories. Virchows Arch., 473. S. S124 - 1. NEW YORK: SPRINGER. ISSN 1432-2307

Koitzsch, U., Heydt, C., Divakar, K., Attig, H., Fassunke, J., Merkelbach-Bruse, S., Fammartino, A. Alessandro, Buettner, R., Kong, Y. and Odenthal, M. (2017). Analysis of Clinical Relevant Mutations by the Novel Gene Reader NGS System. J. Mol. Diagn., 19 (2). S. S55 - 1. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1943-7811

Kostenko, A., Michels, S., Kron, F., Brandes, V, Fischer, R., Nogova, L., Scheffler, M., Fassunke, J., Merkelbach-Bruse, S., Scheel, A., Ueckeroth, F., Sueptitz, J., Gerigk, M., Heydt, C., Glossmann, J. -P, Buettner, R. and Wolf, J. (2016). Improved overall survival following implementation of next generation sequencing in routine diagnostics of advanced lung cancer in Germany: results of the Network Genomic Medicine. Oncol. Res. Treat., 39. S. 305 - 307. BASEL: KARGER. ISSN 2296-5262

Kron, A., Alidousty, C., Scheffler, M., Merkelbach-Bruse, S., Seidel, D., Riedel, R., Ihle, M. A., Michels, S., Nogova, L., Fassunke, J., Heydt, C., Kron, F., Ueckeroth, F., Serke, M., Krueger, S. ORCID: 0000-0002-1658-5993, Grohe, C., Koschel, D., Benedikter, J., Kaminsky, B., Schaaf, B., Braess, J., Sebastian, M., Kambartel, K. -O., Thomas, R., Zander, T., Schultheis, A. M., Buettner, R. and Wolf, J. (2018). Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer. Ann. Oncol., 29 (10). S. 2068 - 2076. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

Kron, A., Riedel, R., Michels, S., Fassunke, J., Merkelbach-Bruse, S., Scheffler, M., Ueckeroth, F., Schueller, M., Pauli, B., Grohe, C., Kaminsky, B., Braess, J., Graeven, U., Krueger, S., Nogova, L., Abdulla, D., Fischer, R., Heydt, C., Buettner, R. and Wolf, J. (2017). Impact of co-occurring genomic alterations on overall survival of BRAF mutated lung cancer patients: results of the Network Genomic Medicine. Oncol. Res. Treat., 40. S. 247 - 248. BASEL: KARGER. ISSN 2296-5262

Kron, A., Riedel, R., Michels, S., Heydt, C., Fassunke, J., Merkelbach-Bruse, S., Scheffler, M., Fischer, R., Abdulla, D., Nogova, L., Ueckeroth, F., Pauli, B., Schueller, M., Serke, M., Koschel, D., Krueger, S., Grohe, C., Kambartel, K., Sebastian, M., Zander, T., Buettner, R. and Wolf, J. (2017). Impact of next generation tyrosine kinase inhibitors (TKI) and co-occurring mutations in ALK-positive NSCLC patients: results of the Network Genomic Medicine. Oncol. Res. Treat., 40. S. 219 - 220. BASEL: KARGER. ISSN 2296-5262

Loeser, H., Heydt, C., Buettner, R. and Markiefka, B. (2017). BRCA diagnostics of ovarian cancer. Molecular tumor testing since the introduction of PARP inhibitor therapy. Pathologe, 38 (2). S. 117 - 126. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1432-1963

Michels, S., Fischer, R., Heydt, C., Ihle, M., Scheffler, M., Scheel, A., Ortiz-Cuaran, S., Nogova, L., Brandes, V, Sos, M., Buettner, R., Merkelbach-Bruse, S. and Wolf, J. (2016). Mechanisms of primary and acquired resistance to 3rd generation EGFR TKI treatment in EGFR mutated lung adenocarcinoma. Oncol. Res. Treat., 39. S. 252 - 254. BASEL: KARGER. ISSN 2296-5262

Michels, S., Heydt, C., Deschler-Baier, B., Ruesseler, V., Stratmann, J., Steinhauser, S., Fischer, R., Scheffler, M., Fassunke, J., Kron, A., Griesinger, F., Gautschi, O., Sebastian, M., Hellmich, M., Heukamp, L., Merkelbach-Bruse, S., Bttner, R. and Wolf, J. (2017). Molecular panel sequencing of pre-treatment samples reveals mechanisms of innate resistance to 3rd generation EGFR TKI treatment in T790M-positive NSCLC patients. Oncol. Res. Treat., 40. S. 134 - 135. BASEL: KARGER. ISSN 2296-5262

Quaas, A., Waldschmidt, D., Alakus, H., Zander, T., Heydt, C., Goeser, T., Daheim, M., Kasper, P., Plum, P., Bruns, C., Brunn, A., Roth, W., Hartmann, N., Bunck, A., Schmidt, M., Goebel, H., Tharun, L., Buettner, R. and Merkelbach-Bruse, S. (2018). Therapy susceptible germline-related BRCA 1-mutation in a case of metastasized mixed adeno-neuroendocrine carcinoma (MANEC) of the small bowel. BMC Gastroenterol., 18. LONDON: BIOMED CENTRAL LTD. ISSN 1471-230X

Rehker, J., Ball, M., Heydt, C., Buettner, R. and Merkelbach-Bruse, S. (2020). Softclipping of gene specific primers after primer extension enrichment to remove artificial sequences from downstream analysis. Eur. J. Hum. Genet., 28 (SUPPL 1). S. 645 - 646. LONDON: SPRINGERNATURE. ISSN 1476-5438

Riedel, R., Kron, A., Michels, S., Fassunke, J., Scheffler, M., Fischer, R., Nogova, L., Abdulla, D., Heydt, C., Ueckeroth, F., Pauli, B., Serke, M., Krueger, S. ORCID: 0000-0002-1658-5993, Grohe, C., Sebastian, M., Koschel, D., Kambartel, K-O., Zander, T., Buettner, R. and Wolf, J. (2017). Impact of next generation TKI and co-occurring mutations in ALK-positive NSCLC patients: Results of the Network Genomic Medicine. Ann. Oncol., 28. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

Riedel, R., Michels, S., Heydt, C., Nogova, L., Fischer, R. N., Abdulla, D. S. Y., Scheffler, M., Merkelbach-Bruse, S., Kobe, C., Schaefer, S., Buettner, R. and Wolf, J. (2018). Durable response to crizotinib in a patient with lung adenocarcinoma harbouring low-level MET amplification but strong MET expression. Oncol. Res. Treat., 41. S. 295 - 297. BASEL: KARGER. ISSN 2296-5262

Ruesseler, V., Heydt, C., Binot, E., Bubendorf, L. and Buettner, R. (2018). Testing of ROS1-positive tumours by IHC displays a FISH-positive subgroup which might not benefit form recently approved drug therapy. Virchows Arch., 473. S. S18 - 2. NEW YORK: SPRINGER. ISSN 1432-2307

Scheffler, M., Gardizi, M., Bos, M., Koenig, K., Michels, S., Fassunke, J., Heydt, C., Kuenstlinger, H., Ihle, M. A., Ueckeroth, F., Albus, K., Serke, M., Gerigk, U., Schulte, W., Toepelt, K., Nogova, L., Zander, T., Engel-Riedel, W., Stoelben, E., Ko, Y. -D., Randerath, W. J., Kaminsky, B., Panse, J., Becker, C., Hellmich, M., Merkelbach-Bruse, S., Buettner, R., Heukamp, L. C. and Wolf, J. (2014). Genetic heterogeneity and lack of prognostic impact of patients with non-small cell lung cancer (NSCLC) harboring PIK3CA mutation. Oncol. Res. Treat., 37. S. 65 - 66. BASEL: KARGER. ISSN 2296-5262

Scheffler, M., Nogova, L., Michels, S., Holzem, A., Chanra, T., Abdulla, D. S. Y., Koleczko, S., Merkelbach-Bruse, S., Fassunke, J., Kron, A., Scheel, A. H., Ihle, M. A., Heydt, C., Westphal, T., Weber, J. -P., Fischer, R. N., Riedel, R., Kaminsky, B., Draube, A., Rothe, A., Kambartel, K. -O., Hillmer, A., Buettner, R. and Wolf, J. (2020). KRAS mutations in never-smoker NSCLC patients: Defining a new patient subgroup. Oncol. Res. Treat., 43 (SUPPL 4). S. 139 - 140. BASEL: KARGER. ISSN 2296-5262

Wagener, S., Heydt, C., Fassunke, J., Ihle, M. A., Carl, C., Buttner, R. and Merkelbach-Bruse, S. (2017). Specific and Reliable Detection of NTRK Rearrangements in IHC-Positive FFPE Samples of Solid Tumours by Nanostring Technology. J. Mol. Diagn., 19 (2). S. S33 - 2. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1943-7811

Wagener, S., Ihle, M. A., Alidousty, C., Heydt, C., Fassunke, J., Merkelbach-Bruse, S. and Buettner, R. (2018). The potential biomarkerHR23b regulates sensitivity towards histone deacetylase inhibitors (HDACi) via the NGFR death receptor pathway. Virchows Arch., 473. S. S1 - 1. NEW YORK: SPRINGER. ISSN 1432-2307

This list was generated on Thu Oct 21 01:36:35 2021 CEST.